Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled dose-ranging trial of inclisiran in Japanese patients with high cardiovascular risk and elevated LDL-C
jRCT2031200313Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of inclisiran in hypercholesterolemia, familial hypercholesterolemia (FH), coronary arteriosclerosis and 1 more (4 arms), sponsored by Novartis. Primary endpoint: Change in LDL-C at Day 180. Started Jan 2021; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)coronary arteriosclerosisatherosclerotic disease
Beyond the preview
Go deeper on jRCT2031200313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200313.